Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy

The current standard treatment option for Human Papillomavirus (HPV) or p16-positive oropharyngeal cancer is full-dose radiation combined with chemotherapy. Results with chemotherapy combined with full-dose radiation therapy leads to high rates of cure; this has called into question whether therapy can be decreased in intensity since both chemotherapy and radiation have long-term side effects. One approach to decrease intensity of treatment is to give radiation alone (excluding chemotherapy) and to decrease radiation therapy dose. The investigator believes that omitting chemotherapy and decrea

Trial Details

NCT ID
NCT06902623
Phase
NA
Sponsor
Georgetown University
Status
RECRUITING
Cancer Type
HPV Positive Head and Neck Cancer
Interventions
  • Radiation
Locations (sample)
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Clinton, Maryland, United States|38.76511,-76.89831

Key Eligibility Criteria

  • Patients must be ≥ 18 years of age on the day of signing informed consent.
  • Patients must have a diagnosis of p16+ and/or HPV+ squamous cell carcinoma of the oropharynx (including base of tongue, glossotonsilar sulcus, tons…
  • clinical stage stage I-II (T1-2 N1 M0, or T3 N0-1 M0 ) (AJCC 8th ed.) SCCA of the oropharynx that would mandate definitive chemoradiation as curren…
  • Subjects must agree to biopsy of areas that are FDG-avid on PET-CT scan 3-4 months after treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HPV Positive Head and Neck Cancer Trials on Trialify →